**Background of GALT Antibodies**
Galactose-1-phosphate uridyltransferase (GALT) is a critical enzyme in the Leloir pathway, responsible for converting galactose to glucose-1-phosphate. Deficiency in GALT activity causes classic galactosemia, a rare autosomal recessive disorder that leads to toxic accumulation of galactose metabolites, resulting in severe neonatal complications (e.g., liver dysfunction, cognitive impairment) if untreated.
GALT antibodies are immunodetection tools developed to identify and quantify the GALT protein in research and diagnostics. These antibodies, often polyclonal or monoclonal, are generated by immunizing animals with purified or recombinant GALT antigens. They enable techniques like Western blotting, ELISA, and immunohistochemistry to assess GALT expression levels, localization, or structural abnormalities in clinical samples (e.g., blood, fibroblasts) or experimental models.
In diagnostics, GALT antibodies aid in confirming galactosemia diagnoses, particularly in cases where enzymatic activity assays are inconclusive. They also support newborn screening programs and carrier testing. Research applications include studying GALT mutations, enzyme kinetics, and molecular mechanisms underlying galactosemia variants (e.g., Duarte variant). Reliable GALT antibodies are essential for advancing therapeutic strategies, such as enzyme replacement or gene therapy, to address this lifelong metabolic disorder.